Conatus Pharmaceuticals Inc. (CNAT)

[lorema]

From their 8-k filing

"
Conatus believes that with the $50 million upfront payment received in December 2016 pursuant to the Collaboration Agreement, the $15 million received in exchange for a convertible promissory note issued to Novartis in February 2017 pursuant to an investment agreement entered into with Novartis in December 2016, the anticipated $7 million option exercise payment, and Novartis bearing 50% of the costs of Conatus’ four ongoing Phase 2b emricasan clinical trials after the license becomes effective, Conatus will have sufficient financial resources to maintain operations and ongoing clinical development activities through the end of 2019."

The question is, why this one now!